Back to search

Switzerland· 69464001

Bosutinib Spirig HC

A bosutinib product containing bosutinibum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01EA04

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedBosutinib Spirig HCATCL01EA04REGISTER NO.69464001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Bosutinib is registered in 15 of 19 countries.

Countries holding a registration under ATC L01EA04 (bosutinib), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Bosutinib · ATC L01EA04

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of bosutinib costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), so markets compare like for like.

  • Switzerland: $65.58 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Bosutinib · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

  • CH Switzerland$65.58
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
bosutinibum
Manufacturer
—
Country
Switzerland (CH)
ATC code
L01EA04
ATC class
Bosutinib
Defined daily dose
0.4 g, O
Swissmedic category
A
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680694640015
    Blist 28 Stk
    CHF 380.7

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

469 interactions on record for bosutinib.

Graded by severity as the source publishes them — 159 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Bosutinib · interactions on record

469 records

  • 159 severe
  • 307 moderate
  • 3 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • AprepitantA04AD12severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Bosutinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bosutinib products

Authorised across Europe · EMA

The same active substance is authorised in 28 EEA countries. Names it is sold under:

  • Austria · Bosutinib Sandoz, Bosutinib Teva
  • Belgium · Bosutinib Eg, Bosutinib Eg (Eurogeneric)
  • Bulgaria · Босутиниб Msn, Босутиниб Зентива
  • Czechia · Bosutinib Msn, Bosutinib Teva
  • Germany · Bosutinib, Bosutinib Al
  • Denmark · Bosutinib Newbury, Bosutinib Sandoz
  • Estonia · Bosutinib Msn
  • Spain · Bosutinib, Bosutinib Vivanta
  • Finland · Bosutinib Stada
  • France · Bosutinib Biogaran, Bosutinib Eg Labo
  • United Kingdom (Northern Ireland) · Bosutinib Dr. Reddy’s, Bosutinib Stada
  • Croatia · Bosutinib Msn, Bosutinib Onkogen
  • Hungary · Bosutinib Onkogen, Bosutinib Sandoz
  • Ireland · Bosutinib Clonmel, Bosutinib Rowex
  • Iceland · Bosulif, Bosutinib Beta
  • Italy · Bosutinib Dr. Reddys, Bosutinib Eg
  • Liechtenstein · Bosulif
  • Lithuania · Bosutinib Msn
  • Luxembourg · Bosutinib Eg
  • Latvia · Bosutinib Msn
  • Malta · Bosutinib, Bosutinib Lotus
  • Netherlands · Bosutinib, Bosutinib Cf
  • Norway · Bosulif, Bosutinib Newbury
  • Poland · Bosutinib Msn, Bosutinib Onkogen
  • Portugal · Bosutinib Teva
  • Romania · Bosutinib Teva
  • Sweden · Bosutinib Newbury, Bosutinib Sandoz
  • Slovenia · Bosutinib Msn

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5904e511-027a-4a0d-82c2-e93d94b85308
GET /v1/drugs/5904e511-027a-4a0d-82c2-e93d94b85308?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "bosutinibum 100 mg",
  "valid_from": "2025-04-01",
  "limitations": "[{\"description\":\"Bosutinib Spirig HC ist indiziert für die Behandlung von erwachsenen Patienten mit neu diagnostizierter Philadelphia-Chromosom positiver chronischer myeloischer Leukämie (Ph+ CML) in der chronischen Phase (CP).<br>\\nBosutinib Spirig HC ist indiziert für die Behandlung von erwachsenen Patienten mit Philadelphia-Chromosom positiver chronisch myeloischer Leukämie (Ph+ CML) in der chronischen Phase, in der akzelerierten Phase sowie in der Blastenkrise, nach Vorbehandlung mit einem oder mehreren c-abl Tyrosinkinase Inhibitoren und wenn eine Behandlung mit Imatinib, Nilotinib oder Dasatinib nicht in Frage kommt.<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2025-04-01\",\"validTo\":null}]",
  "galenic_form": "Filmtabl 100 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2025-04-01",
  "self_retention_pct": 10
}

See everything about bosutinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.